Note: These statements are for information purposes and should not replace the clinical judgment of a physician, who must ultimately determine the appropriate treatment for each patient.

Background: Maternal mortality rates in Brazil remain above the goals established by the United Nations Sustainable Development Goals. Heart disease is estimated to affect 4% of all pregnancies and remains by itself the main indirect obstetric cause of maternal death. In the last decades, a significant improvement in the prognosis of heart diseases has made pregnancy possible in women with heart disease and provided better maternal and fetal outcomes.Objectives: To establish a multicenter Brazilian Registry of pregnant women with heart disease; to study the causes of immediate and late maternal mortality; and to assess the prevalence of heart disease in the country's macro-regions.Methods: This is an observational study, with retrospective and prospective stages, of the clinical and obstetric progression of pregnant women with heart disease. These women consecutively received care during pregnancy and will be followed up for up to a year after delivery at public and private hospitals with infrastructure for the execution of this project, a principal investigator, and approval by Ethics and Research Committees.Results: Our results will be presented after data collection and statistical analysis, aiming to demonstrate immediate and late maternal mortality rates, as well as the prevalence of heart disease in the country and its cardiovascular and obstetric complications during pregnancy.Conclusions: REBECGA will be the Brazilian Registry of heart disease and pregnancy and it will contribute to planning preventive measures, raising financial resources for the improvement of high-risk prenatal care, and reducing immediate and late maternal mortality due to heart disease.

Oliveira et al. Posicionamento sobre a Saúde Cardiovascular nas Mulheres -2022 Posicionamento sobre a Saúde Cardiovascular nas Mulheres -2022 O relatório abaixo lista as declarações de interesse conforme relatadas à SBC pelos especialistas durante o período de desenvolvimento deste posicionamento, 2022 Especialista Tipo de relacionamento com a indústria Alexandra Oliveira de Mesquita Nada a ser declarado Alexandre Jorge Gomes de Lucena Nada a ser declarado Andréa Araujo Brandão Declaração financeira A -Pagamento de qualquer espécie e desde que economicamente apreciáveis, feitos a (i) você, (ii) ao seu cônjuge/ companheiro ou a qualquer outro membro que resida com você, (iii) a qualquer pessoa jurídica em que qualquer destes seja controlador, sócio, acionista ou participante, de forma direta ou indireta, recebimento por palestras, aulas, atuação como proctor de treinamentos, remunerações, honorários pagos por participações em conselhos consultivos, de investigadores, ou outros comitês, etc. Provenientes da indústria farmacêutica, de órteses, próteses, equipamentos e implantes, brasileiras ou estrangeiras: -Servier: Acertil, Acertalix, Acertanlo, Triplixan. Outros relacionamentos Financiamento de atividades de educação médica continuada, incluindo viagens, hospedagens e inscrições para congressos e cursos, provenientes da indústria farmacêutica, de órteses, próteses, equipamentos e implantes, brasileiras ou estrangeiras: -Servier: Acertil, Acertalix, Acertanlo, Triplixan.

Nota: estes posicionamentos se prestam a informar e não a substituir o julgamento clínico do médico que, em última análise, deve determinar o tratamento apropriado para seus pacientes.

The prevalence of depression varies from 1 to 17% in different geographic regions, and its incidence is 70% higher in women than men. Today, depression affects more than 300 million people worldwide, affecting twice as many women from adolescence to adulthood. In addition to this earlier onset, depression in women tends to be more severe. Cardiovascular disease and depression are chronic diseases that have a major impact on cardiovascular and all-cause morbidity and mortality, with evidence of a two-way relationship between them, in which depression is a predictor of cardiovascular disease and vice versa. In females, the degree of illness and prognosis are more severe when both diseases are present, than when diagnosed alone. In patients with acute or chronic cardiovascular disease, especially women, a systematic screening for depression should be considered as a preventive strategy of cardiovascular events, aiming to reduce the risk of future events. There are still no clinical studies designed to assess the impact of antidepressant treatment on cardiovascular outcomes in women.